NEJM Publishes Positive Phase 3 Results for Priovant’s Brepocitinib in Dermatomyositis

Priovant Therapeutics has announced the formal publication of positive Phase 3 VALOR trial results for brepocitinib in the New England Journal of Medicine (NEJM). The study evaluated the efficacy and safety of the drug in adults suffering from dermatomyositis (DM), a rare and debilitating autoimmune disease. The publication in such a prestigious medical journal provides high-level clinical validation, which is a critical milestone for future regulatory approval and market adoption. For partners Roivant Sciences (ROIV) and Pfizer (PFE), this development serves as a significant de-risking event in their biotechnology portfolios. Clinical data indicated substantial improvement in patient outcomes, positioning brepocitinib as a potential leading treatment for this underserved patient population. Market analysts view this formal validation as a positive catalyst for the long-term commercial viability of the therapy.

Sources:globenewswire.combusinesswire.com